Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ProMIS NeurosciencesVallon PharmaceuticalsEmerald Health TherapeuticsRua Life SciencesIntelGenx Technologies
SymbolTSE:PMNNASDAQ:VLONCVE:EMHLON:RUACVE:IGX
Price Information
Current PriceC$0.22$4.66C$0.29GBX 148.50C$0.57
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.30.50.00.9
Analysis Score0.00.00.00.00.0
Community Score2.70.02.00.02.6
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.01.7
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market CapC$67.31 million$31.74 millionC$34.02 million£34.39 millionC$30.87 million
BetaN/AN/AN/AN/AN/A
Average Volume439,21367,865719,59155,39253,378
Sales & Book Value
Annual RevenueC$1,787.00N/AC$13.02 million£835,000.00C$1.54 million
Price / Sales37,665.92N/A4.5739.4541.31
CashflowC$0.00 per shareN/AC$0.34 per shareGBX 5.94 per shareC$0.02 per share
Price / Cash55.00N/A0.8625.0027.50
Book ValueC$0.00 per shareN/AC$0.40 per shareGBX 17 per shareC($0.01) per share
Price / Book-55.00N/A0.730.09-63.33
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.02)N/AC($0.70)GBX (8.20)C($0.07)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A35.45%11.22%565.41%
Current Ratio0.52%N/A2.97%1.67%0.99%
Quick Ratio0.46%N/A2.61%1.53%0.80%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A2161748
Shares Outstanding305.95 million6.81 million205.03 million22.19 million111.91 million
Next Earnings Date5/12/2021 (Estimated)7/5/2021 (Estimated)6/17/2021 (Estimated)N/A5/13/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
IntelGenx Announces Intention to Amend Convertible Unsecured Promissory NotesIntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes
finance.yahoo.com - April 9 at 9:06 AM
IntelGenx is a double from here, says Leede Jones GableIntelGenx is a double from here, says Leede Jones Gable
cantechletter.com - March 29 at 7:18 PM
IntelGenx Reports Fourth Quarter and Full-Year 2020 Financial ResultsIntelGenx Reports Fourth Quarter and Full-Year 2020 Financial Results
finance.yahoo.com - March 25 at 6:11 PM
IntelGenx Technologies (IGX) Scheduled to Post Quarterly Earnings on ThursdayIntelGenx Technologies (IGX) Scheduled to Post Quarterly Earnings on Thursday
americanbankingnews.com - March 19 at 10:37 AM
IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ(TM)-Based Disintegrating THC Oral FilmIntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ(TM)-Based Disintegrating THC Oral Film
stockhouse.com - February 17 at 11:33 PM
IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral FilmIntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral Film
markets.businessinsider.com - February 17 at 8:31 AM
IntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General CounselIntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel
morningstar.com - January 12 at 9:47 PM
IntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2020 Results - Earnings Call TranscriptIntelGenx Technologies Corp. (IGXT) CEO Horst Zerbe on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 11:35 PM
IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to ...IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to ...
apnews.com - November 12 at 6:34 PM
IntelGenx Reports Third Quarter 2020 Financial ResultsIntelGenx Reports Third Quarter 2020 Financial Results
markets.businessinsider.com - November 12 at 6:34 PM
IntelGenx: 3Q Earnings SnapshotIntelGenx: 3Q Earnings Snapshot
houstonchronicle.com - November 12 at 6:34 PM
IntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to Cannabis-Containing Oral FilmsIntelGenx Announces Issuance of U.S. Patent for Novel Technology Applicable to Cannabis-Containing Oral Films
markets.businessinsider.com - November 11 at 12:31 PM
IntelGenx Announces Publication of a Study Evaluating Montelukasts Effect on Neurological AgingIntelGenx Announces Publication of a Study Evaluating Montelukast's Effect on Neurological Aging
marketwatch.com - November 9 at 8:20 PM
IntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological AgingIntelGenx Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging
news.yahoo.com - November 9 at 9:52 AM
Heritage Cannabis Signs Letter of Intent with IntelGenx for Long-Term Cannabis Filmstrip Supply AgreementHeritage Cannabis Signs Letter of Intent with IntelGenx for Long-Term Cannabis Filmstrip Supply Agreement
news.yahoo.com - October 29 at 10:05 AM
IntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply AgreementIntelGenx Signs Letter of Intent with Heritage Cannabis for Long-Term Cannabis Filmstrip Supply Agreement
news.yahoo.com - October 29 at 10:05 AM
Tetra Bio-Pharma gets global rights to Adversa mucoadhesive technology for its Dronabinol drug from IntelGenxTetra Bio-Pharma gets global rights to Adversa mucoadhesive technology for its Dronabinol drug from IntelGenx
proactiveinvestors.com - October 28 at 12:29 PM
IntelGenx Amends Stock OptionsIntelGenx Amends Stock Options
benzinga.com - August 24 at 6:21 PM
IntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based PsychedelicsIntelGenx Enters into Feasibility Agreement with ATAI Life Sciences to Develop Pharmaceutical-Grade Polymeric Film-Based Psychedelics
benzinga.com - August 20 at 9:03 AM
IntelGenx Reports Amendment of Stock Option PlanIntelGenx Reports Amendment of Stock Option Plan
finance.yahoo.com - July 15 at 6:21 PM
IntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of DebentureholdersIntelGenx Announces Intention to Issue Shares in Payment of Principal on Outstanding Debentures, and Meeting of Debentureholders
www.wallstreet-online.de - May 28 at 8:15 AM
IntelGenx Confirms Type A Meeting with the FDA Regarding RIZAPORT® VersaFilm®IntelGenx Confirms Type A Meeting with the FDA Regarding RIZAPORT® VersaFilm®
www.benzinga.com - May 27 at 9:27 AM
IntelGenx Announces Intention to Amend Convertible DebenturesIntelGenx Announces Intention to Amend Convertible Debentures
www.benzinga.com - May 12 at 9:06 AM
IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®
markets.businessinsider.com - January 13 at 5:09 PM
IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ PlatformIntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform
www.globenewswire.com - January 9 at 4:22 PM
DateCompanyBrokerageAction
2/17/2019ProMIS NeurosciencesNoble FinancialReiterated Rating
10/11/2019Emerald Health TherapeuticsJefferies Financial GroupLower Price Target
8/11/2020Rua Life SciencesShore CapitalReiterated Rating
10/28/2019IntelGenx TechnologiesEchelon Wealth PartnersReiterated Rating
5/15/2018IntelGenx TechnologiesHC WainwrightLower Price Target
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.